

Recombinant Human MS4A1/CD20 Protein-VLP

Catalog No.: RP00583 **Recombinant**

Sequence Information

Species	Gene ID	Swiss Prot
Human	931	P11836-1

Tags
No Tag

Synonyms
MS4A1; CD20; MS4A-1; B1; Bp35; CD20 receptor; CD20S7; CVID5; LEU-16; Ly-44; MS4A2; S7

Product Information

Source	Purification
HEK293 cells	> 95% by HPLC

Calculated MW	Observed MW
34.3 kDa	

Endotoxin
< 1 EU/μg of the protein by LAL method

Formulation
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization. Notice: If you need it for immunization, Do Not use any adjuvant.

Reconstitution
Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stabilizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize free-thaw cycles.

Contact

☎ | 400-999-6126

✉ | cn.market@abclonal.com.cn

🌐 | www.abclonal.com.cn

Background

B-lymphocyte antigen CD20 or CD20 is an activated-glycosylated phosphoprotein expressed on the surface of all B-cells beginning at the pro-B phase (CD45R , CD117) and progressively increasing in concentration until maturity. CD20 is the target of the monoclonal antibodies rituximab, ocrelizumab, obinutuzumab, ofatumumab, ibritumomab tiuxetan, tositumomab, and ublituximab, which are all active agents in the treatment of all B cell lymphomas, leukemias, and B cell-mediated autoimmune diseases.


Basic Information

Description
Recombinant Human MS4A1/CD20 Protein-VLP is produced by HEK293 cells expression system. The target protein is expressed with sequence (Met1-Pro297) of Human MS4A1/CD20 (Accession #P11836-1) fused with No Tag.


Bio-Activity

Storage
Store at -20°C. Store the lyophilized protein at -20°C to -80 °C up to 1 year from the date of receipt. After reconstitution, the protein solution is stable at -20°C for 3 months, at 2-8°C for up to 1 week. Avoid repeated freeze/thaw cycles.


Validation Data




The purity of Human CD20 VLP is greater than 95% as determined by SEC-HPLC.



Immobilized Human CD20 VLP at 5 µg/mL (100 µL/Well) on plate on the plate. Dose response curve for Ofatumumab, hFc Tag with the EC₅₀ of 10.5ng/mL determined by ELISA (QC Test).



Immobilized Human CD20 VLP at 5 µg/mL (100 µL/Well) on plate on the plate. Dose response curve for Rituximab, hFc Tag with the EC₅₀ of 11.4ng/mL determined by ELISA (QC Test).



Immobilized Human CD20 VLP at 5 µg/mL (100 µL/well) on the plate. Dose response curve for Obinituzumab, hFc Tag with the EC₅₀ of 1.7ng/mL determined by ELISA.